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S U M M A R Y
Background: Tigecycline is a relatively new glycylcycline antimicrobial, active in vitro against a variety of
Gram-positive and Gram-negative organisms. In this study we evaluated the outcomes of
spondylodiscitis cases treated with tigecycline-including therapies retrospectively.
Methods: All adult (age >18 years) cases with a diagnosis of spondylodiscitis, who were treated with a
tigecycline-including therapy between 2007 and 2011, were included in the study. The primary efﬁcacy
outcome was clinical success with tigecycline at the end of induction, while the secondary efﬁcacy
outcome was maintenance of success through 3 months following completion of induction.
Results: A total of eight spondylodiscitis cases fulﬁlled the study inclusion criteria. All cases had back
pain, restricted mobility, magnetic resonance ﬁndings associated with spondylodiscitis, and
microbiology or pathological ﬁndings related to spondylodiscitis. All had post-neurosurgical
spondylodiscitis. In ﬁve cases, tigecycline was started in accordance with the antibacterial susceptibility
results from intervertebral tissue biopsy cultures, whereas in three it was started empirically. All cases
had received several different antibacterials with failure before receiving tigecycline. The mean duration
of tigecycline treatment was 37  21 days. One case was lost to follow-up after 2 days of tigecycline.
Primary and secondary success was achieved in the remaining seven cases.
Conclusions: These limited data suggest that tigecycline may have a role in the treatment of refractory
spondylodiscitis cases.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Healthcare-associated/nosocomial infections are increasing
and important causes of morbidity after spinal surgery in many
countries around the world.1–3 The efﬁcacy of treatment choices is
very limited in multidrug-resistant (MDR) Acinetobacter bauman-
nii. For example, there is currently no universally effective
antibiotic against MDR. Hence, treatment regimens are tailored
according to antibiotic resistance patterns and available anti-
biotics.4–6* Corresponding author. Tel.: +90 232 3903305.
E-mail address: Oguz.resat.sipahi@ege.edu.tr (O.R. Sipahi).
http://dx.doi.org/10.1016/j.ijid.2014.01.027
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Tigecycline is a relatively new glycylcycline antimicrobial, active
in vitro against a variety of Gram-positive and Gram-negative
organisms, including nosocomial MDR pathogens such as methicil-
lin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant
enterococci (VRE), extended-spectrum beta-lactamase (ESBL) pro-
ducers, and carbapenem-resistant A. baumannii. The US Food and
Drug Administration (FDA) has approved tigecycline for the
treatment of complicated intra-abdominal infections, complicated
skin and skin structure infections, and community-acquired
pneumonia (CAP). However, its pharmacological and microbiolog-
ical proﬁles have encouraged physicians to use the drug in hospital-
acquired pneumonia (HAP), ventilator-associated pneumonia (VAP),
and meningitis caused by MDR and tigecycline-sensitive pathogens
featuring limited therapeutic options. Nevertheless, data regardingciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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osteomyelitis are very limited.4–6 In this study we retrospectively
evaluated the outcomes of spondylodiscitis cases who were treated
with a tigecycline-including therapy.
2. Patients and methods
This study was performed at a tertiary-care general teaching
hospital with an infectious diseases ward of 31 beds. All adult (age
>18 years) patients with spondylodiscitis who were treated with a
tigecycline-including therapy between January 2007 and August
2011 were included in the study. All cases with the following four
criteria were accepted as spondylodiscitis: (1) symptoms of back
pain and restricted mobility, (2) magnetic resonance imaging
(MRI) ﬁndings associated with spondylodiscitis, (3) increased
erythrocyte sedimentation rate (ESR) and/or C-reactive protein
(CRP) levels, (4) intervertebral disc sample culture yielding
spondylodiscitis-associated organisms, or pathology result associ-
ated with spondylodiscitis.
Demographic, clinical, and laboratory data and predisposing
factors, as well as information on response to treatment and
outcome were obtained from each patient’s hospital records.
Intervertebral disc samples were obtained by trucut biopsy and/or
during the surgery. Samples were sent routinely in thioglycollate
broth, which was incubated for up to 72 h at 37 8C and passaged
into eosin–methylene blue agar and 5% sheep blood agar. Bacterial
identiﬁcation was performed with an automated system (VITEK,
bioMe´rieux, Marcy l’Etoile, France).
Antibacterial susceptibility tests were performed by Kirby–
Bauer disk diffusion method, as described by the Clinical and
Laboratory Standards Institute (CLSI).7 The FDA clinical minimum
inhibitory concentration (MIC) breakpoints for Enterobacteriaceae
(2 mg/l, sensitive) were used for tigecycline susceptibility in
Acinetobacter spp. The primary efﬁcacy outcome was clinical
success with tigecycline at the end of induction, while the
secondary efﬁcacy outcome was maintenance of success through
3 months following completion of induction.
3. Results
A total of eight spondylodiscitis cases (six female, two male,
aged 59  11 years; Table 1) had received a tigecycline-including
therapy for spondylodiscitis, which was diagnosed according to the
criteria above. The ages and characteristics of these eight cases are
shown in Table 1.
3.1. Clinical presentation and diagnosis
All but one of the cases had fever on admission. In addition to
back pain and restricted mobility, two cases had paraparesis. Four
cases had diabetes mellitus as the underlying disease. All had
spondylodiscitis secondary to previous spinal surgery: three had a
lumbar canal stenosis, two had a lumbar hernia, two had a thoracic
canal stenosis, and one had a cervical hernia. The time to
spondylitis after surgery was 2 months in six cases (Table 1).
Intervertebral disc sample cultures yielded the etiology in ﬁve
cases (Table 1); the pathology, symptoms, and MRI ﬁndings
supported the diagnosis in the remaining three cases. Brucellosis
serology as well as tuberculosis PCR and culture were negative for
all cases. MRI and microbiological cultures, as well as ESR and CRP
levels, are shown in Table 1.
3.2. Treatment
All cases had received two to eight different antibacterials with
failure before receiving tigecycline (Table 1). Tigecycline was givenas a 100-mg loading dose, followed by 50 mg every 12 h in all
cases. In ﬁve cases, tigecycline was started in accordance with the
results of the antibacterial susceptibility testing of intervertebral
tissue biopsy cultures, whereas in the remaining cases it was
started empirically (Table 1).
Tigecycline was used as monotherapy in four cases, while it was
used as a part of combination therapy in the other four (Table 1).
No additional therapy was used after tigecycline in ﬁve cases,
whereas two cases received further therapy (Table 1).
Four cases (Table 1, cases 4–7) underwent additional neuro-
surgery for the spondylodiscitis during the tigecycline therapy
period.
3.3. Clinical efﬁcacy
One case was lost to follow-up after being discharged at her
request from our setting. Primary and secondary success was
achieved in the remaining seven cases, with a remarkable
response, including a decrease in inﬂammatory parameters
(Table 1) and relief of the clinical and radiological ﬁndings at
the end of the intravenous tigecycline therapy. Despite clinical and
radiological improvement, cases 3 and 5 (Table 1) could be
mobilized only with support. None of the seven cases with a
successful outcome developed relapse during at least 1 year of
follow-up.
3.4. Adverse events
Three of eight cases (cases 1, 2, and 5) experienced nausea and
vomiting secondary to tigecycline (Table 1). Ondansetron was
started as anti-emetic in all of these cases. Despite ondansetron,
one of the three cases (case 2) had their treatment switched to
another regimen.
4. Discussion
Tigecycline is a semi-synthetic derivative of minocycline and is
the ﬁrst antibiotic in the glycylcycline class. Although it is a
bacteriostatic agent, it is used successfully in combination with
other agents for the treatment of MDR bacterial meningitis and
other infections.5
Spondylodiscitis is a rare complication of spinal surgery.
However, despite developments in antimicrobial therapy, it may
be associated with signiﬁcant morbidity. The diagnosis depends on
the clinical and laboratory ﬁndings, as well as MRI and microbiol-
ogy or pathology.1–6 In our series, the diagnosis was supported by
both MRI and microbiological evidence and/or pathological
ﬁndings associated with osteomyelitis.
The main risk factors for vertebral osteomyelitis are invasive
interventions including neurosurgery, endocarditis, underlying
carcinoma, pyelonephritis, and advanced age.8 All the cases
presented here had spondylodiscitis secondary to neurosurgery.
In addition ﬁve were aged >50 years and four had diabetes
mellitus.
Brucellosis and tuberculosis are common etiologic agents of
spondylodiscitis in Turkey.9 Brucellosis serology and bacterial
culture, as well as mycobacterial culture and PCR, were negative in
all the cases presented.
The recommendation for nosocomial vertebral osteomyelitis is
vancomycin.1–5 All eight cases had received vancomycin or
teicoplanin before receiving tigecycline. In addition, since Gram-
negative organisms are not rare in our setting, all cases received
additional antibiotics against Gram-negative bacteria. However,
since they did not have a clinical response to the previous two to
eight therapies, tigecycline was started as salvage therapy. In the
Table 1
Age, gender, time to spondylitis after surgery, radiological and microbiological ﬁndings, treatment modalities before and after tigecycline, reason for including tigecycline in
therapy, pre- and post-treatment ESR and CRP data of the cases
Patient Age/gender Time after surgery
to spondylodiscitis/
MRI ﬁnding
Microbiological
results of
intervertebral
biopsy cultures
Therapy before
tigecycline
Reason for tigecycline/
tigecycline-including
therapy
Therapy after
tigecycline
Admission and
discharge ESR
(mm/h)/CRP (mg/dl)
1 49/female 15 days/L1–L4
spondylodiscitis
and abscess
Methicillin-resistant
coagulase-negative
staphylococci,
Pseudomonas
aeruginosa, Klebsiella
pneumoniae
Ceftriaxone (6 days),
teicoplanin (6 days),
linezolid (45 days),
ceftazidime (13 days),
meropenem (16 days)
Guided therapy after
failure with previous
therapies/meropenem
(70 days) + tigecycline
(70 days) + rifampin
(30 days)
Ceﬁxime + amoxicillin/
clavulanate + rifampin
(180 days)
51/10
10/0.26
2 64/male 45 days/L3–L4
spondylodiscitis
Acinetobacter
baumannii
Ceftazidime (9 days),
teicoplanin (9 days),
piperacillin/
tazobactam (7 days),
linezolid (7 days)
Guided therapy/
tigecycline (25 days)
Doxycycline (42 days),
netilmicin (25 days) +
sulbactam (15 days), 9
months doxycycline
monotherapy
63/2.15
19/0.45
3 49/female 60 days/T8–T9
spondylodiscitis
Salmonella enteritidis,
Enterobacter cloacae
Teicoplanin (9 days),
linezolid (9 days),
doripenem (15 days),
ciproﬂoxacin (32 days)
Guided therapy after
failure with previous
therapies/ tigecycline
(42 days) +
meropenem (42 days)
+ ciproﬂoxacin (42
days)
No additional
treatment
63/8.53
45/0.98
4 50/female 30 days/L4–L5
spondylodiscitis
No pathogen Ceftriaxone (20 days),
teicoplanin (20 days)
Empirical therapy/
tigecycline (42 days
monotherapy)
No additional
treatment
98/6.5
2/0.5
5 66/male 10 days/L4–L5
spondylodiscitis +
paravertebral and
epidural abscess
No pathogen Ceftriaxone (21 days),
teicoplanin (21 days)
Empirical therapy,
tigecycline (56 days
monotherapy)
No additional
treatment
95/23
30/0.12
6 52/female 40 days/T7–T8
abscess collection,
T7 osteomyelitis
Acinetobacter
baumannii
Imipenem (3 days),
linezolid (3 days)
Guided therapy/
tigecycline (2 days) +
netilmicin (2 days)
Lost to follow-up -/9.27
-/5.76
7 60/female 5.5 years/T7–T8
osteomyelitis
Methicillin-resistant
coagulase-negative
staphylococci
Teicoplanin (50 days),
rifampin (50 days),
levoﬂoxacin(30 days),
fusidic acid (30 days),
linezolid (35 days),
daptomycin (44 days),
cefepime (9 days),
meropenem (14 days)
Guided therapy after
failure with previous
therapies/ tigecycline
(28 days
monotherapy)
No additional
treatment
80/2.54
65/0.50
8 81/female 6 months/L3–L4
spondylodiscitis +
lumbar stenosis
No pathogen Ampicillin/sulbactam
(31 days), ceftriaxone
(14 days), teicoplanin
(23 days), linezolid (22
days), daptomycin (14
days)
Empirical therapy/
tigecycline (31 days) +
rifampin (31 days)
No additional
treatment
95/1.49
55/0.38
MRI, magnetic resonance imaging; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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combined with another antibiotic.
Data related to tigecycline in osteomyelitis are very rare in the
literature. Tigecycline was reported to have similar antibacterial
efﬁcacy as teicoplanin or vancomycin in MRSA osteomyelitis in the
rabbit osteomyelitis model.10,11 Twilla et al.3 reported a successful
outcome of MRSA osteomyelitis with 4 weeks telavancin, 1 week of
tigecycline, and 2 weeks of oral linezolid. Polilli et al.2 reported
failure with tigecycline in osteomyelitis in a renal transplant
recipient with Anderson–Fabry disease. Kuo et al.4 reported two
cases of osteomyelitis successfully treated with tigecycline.
Recently Grifﬁn et al.6 reported 85% success in 13 osteomyelitis
cases (one vertebral osteomyelitis) for the primary efﬁcacy
endpoint of clinical success used in our study. Nine of these 13
patients who were treated successfully returned for evaluation at 3
months; 6/9 evaluable patients (67%) attained the secondary
endpoint of maintenance of success used in our study. In the
presented series, four cases received tigecycline monotherapy,
whereas four cases received additional combined antibiotics due tocoexisting pathogens. The most common adverse effect was
nausea and vomiting, which necessitated drug cessation in one
case.
In our series, three cases were started on tigecycline as
empirical therapy after failure with at least two antibiotics. We
chose tigecycline since the MRSA, carbapenem-resistant Acineto-
bacter, and ESBL-producing Klebsiella pneumoniae and Escherichia
coli rates are high in our setting. Such MDR infections are quite
common in most parts of the world, as well as in our setting.12
Among all nosocomial infections in the clinics that are under active
nosocomial infection surveillance in our setting, the carbapenem-
resistant Acinetobacter spp rate was 89.6% (189/211), ESBL-
producing K. pneumoniae rate was 66.1% (111/168), ESBL-produc-
ing E. coli rate was 60% (120/200), and MRSA rate was 50% (53/106)
(Bilgin Arda, unpublished data).
Although this is a limited experience in a small cohort without
any comparator agent, our data suggest that tigecycline may have a
role in the treatment of refractory spondylodiscitis cases. To our
knowledge, this is the largest set of data reported related to
O.R. Sipahi et al. / International Journal of Infectious Diseases 23 (2014) 16–19 19tigecycline in the treatment of spondylodiscitis. A clinical study
involving larger osteomyelitis cohorts may increase the evidence
related to this problem.
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